{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Noordraven EL"],"funding":["NCATS NIH HHS"],"pagination":["655"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6131864"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["11(1)"],"pubmed_abstract":["Objective
Offering a financial incentive ('Money for Medication') is effective in improving adherence to treatment with depot antipsychotic medications. We investigated the cost-effectiveness in terms of medical costs and judicial expenses of using financial incentives to improve adherence. The effects of financial incentives on depot medication adherence were evaluated in a randomised controlled trial. Patients in the intervention group received €30 a month over 12 months if antipsychotic depot medication was accepted. The control group received mental health care as usual. For 133 patients outcomes were calculated based on self-reported service use and delinquent behaviour and expressed as standard unit costs to value resource use.Results
The financial incentive resulted in higher average costs related to mental health care (€449.6 versus €355.7). and lower medical costs related to other healthcare services (€52.0 versus €78.4). Relevant differences in social costs related to delinquent behaviour were not found. Although wide confidence intervals indicate uncertainty, incremental cost-effectiveness ratio's (ICER) indicate that it costs €2080 for achieving a 20% increase in adherence or €3332 for achieving over 80% adherence. In sum, offering money as financial incentive for increasing compliance did not lead to an overall cost reduction as compared to care as usual. Trial registration NTR2350, 01 June 2010."],"journal":["BMC research notes"],"pubmed_title":["Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial."],"pmcid":["PMC6131864"],"funding_grant_id":["R43 TR002350"],"pubmed_authors":["Wierdsma AI","Mulder CL","Blanken P","Noordraven EL","Bloemendaal AFT"],"additional_accession":[]},"is_claimable":false,"name":"Medical and social costs after using financial incentives to improve medication adherence: results of a 1 year randomised controlled trial.","description":"Objective
Offering a financial incentive ('Money for Medication') is effective in improving adherence to treatment with depot antipsychotic medications. We investigated the cost-effectiveness in terms of medical costs and judicial expenses of using financial incentives to improve adherence. The effects of financial incentives on depot medication adherence were evaluated in a randomised controlled trial. Patients in the intervention group received €30 a month over 12 months if antipsychotic depot medication was accepted. The control group received mental health care as usual. For 133 patients outcomes were calculated based on self-reported service use and delinquent behaviour and expressed as standard unit costs to value resource use.Results
The financial incentive resulted in higher average costs related to mental health care (€449.6 versus €355.7). and lower medical costs related to other healthcare services (€52.0 versus €78.4). Relevant differences in social costs related to delinquent behaviour were not found. Although wide confidence intervals indicate uncertainty, incremental cost-effectiveness ratio's (ICER) indicate that it costs €2080 for achieving a 20% increase in adherence or €3332 for achieving over 80% adherence. In sum, offering money as financial incentive for increasing compliance did not lead to an overall cost reduction as compared to care as usual. Trial registration NTR2350, 01 June 2010.","dates":{"release":"2018-01-01T00:00:00Z","publication":"2018 Sep","modification":"2025-04-18T14:57:24.484Z","creation":"2019-03-26T23:55:37Z"},"accession":"S-EPMC6131864","cross_references":{"pubmed":["30201054"],"doi":["10.1186/s13104-018-3747-1"]}}